metricas
covid
Enfermedades Infecciosas y Microbiología Clínica (English Edition) Recovery of the increasing pattern of sexually transmitted infections (STI) afte...
Journal Information
Visits
498
Vol. 43. Issue 6.
Pages 345-352 (June - July 2025)
Original article
Full text access
Recovery of the increasing pattern of sexually transmitted infections (STI) after the COVID-19 pandemic: The case of gonorrhea in Catalonia, Spain
Recuperación del patrón de incremento de las infecciones de transmisión sexual (ITS) después de la pandemia de COVID-19: el caso de la gonococia en Cataluña, España
Visits
498
Evelin López-Corbetoa,b,
Corresponding author
elcorbeto@iconologia.net

Corresponding author.
, Julia Valera Palomac,d, Marcos Montoro Fernándeza, Rossie Lugo Colóna,b, Laura Clotet Romeroe, Víctor Guadalupe Fernandezf, Pilar Ciruela Navasg, Jordi Casabona Barbaraa,b,d, on behalf of the Grupo de ITS de la comisión de vigilancia epidemiológica de Cataluña g,h
a Centro de Estudios Epidemiológicos sobre las ITS y Sida de Cataluña (CEEISCAT), Badalona, Barcelona, Spain
b CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
c Servei de Medicina Preventiva i Epidemiologia, Hospital Universitari Germans Trias i Pujol, Gerència Metropolitana Nord, ICS, Badalona, Barcelona, Spain
d Departament de Pediatria, d’Obstetrícia, Ginecologia i de Medicina Preventiva i Salut Pública, Universitat Autónoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain
e Servei de Vigilància Epidemiològica i Resposta a Emergències de Salut Pública, Sub-direcció Regional al Vallès Occidental i Vallès Oriental, Agència de Salut Pública de Cataluña, Barcelona, Barcelona, Spain
f Servei de Vigilància Epidemiològica i Resposta a Emergències de Salut Pública, Sub-direcció Regional a la Catalunya Central, Agència de Salut Pública de Catalunya, Barcelona, Spain
g Subdirecció General de Vigilància i Resposta a Emergències de Salut Pública (SGVRESP), Agència de Salut Pública de Catalunya, Barcelona, Spain
h Subdirecció General d’Addiccions, VIH, ITS i Hepatitis Víriques. Agència de Salut Pública de Catalunya, Barcelona, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (2)
Table 1. Changes in the incidence rate per 100,000 population of gonorrhoea by gender and origin, Catalonia 2017–2023.
Tables
Table 2. Clinical-epidemiological characteristics of notified cases of gonorrhoea in Catalonia according to the study period, 2017-2023.
Tables
Show moreShow less
Abstract
Introduction

Sexually transmitted infections (STI) have shown a sustained increase in recent years. Changes in epidemiological patterns highlight the need to adapt public health strategies for their prevention and control. The objective of this study is to describe the trend of reported gonorrhea cases in Catalonia (Spain) from 2017 to 2023 and to compare the epidemiological pattern of reported cases before, during, and after the COVID-19 pandemic.

Methods

Descriptive analysis of reported gonorrhea cases in Catalonia among individuals aged ≥ 14 years between 2017 and 2023. Incidence rates (IR) were calculated overall and by sex, age, and origin. A descriptive analysis was conducted to compare reported cases across the pre-pandemic (2017−2019), pandemic (2020), and post-pandemic (2021−2023) periods.

Results

The IR of gonorrhea showed an average increase of 32.9% between 2017−2019 and 37.9% between 2021−2023, reaching 164.0 cases per 100,000 inhabitants in 2023. During the pandemic, there was an increase in the proportion of cases among MSM (13.3%), alcohol use (40.0%), having ≥ 6 sexual partners (30.5%), and new sexual partners (74.3%). In the post-pandemic period, the highest percentage increase was observed in women (115.7%), Spanish nationals (124.9%), cases reported in sexual and reproductive health units (30.9%), symptomatic cases (58.0%), and reinfections (33.0%). Additionally, there was a decrease in the average age, particularly among women, in contact tracing studies (13.1%), and in antibiotic resistance.

Conclusions

Gonorrhea continues to rise, especially among young people and women. Strengthening its visibility and prioritizing it in STI prevention and control programs is crucial to mitigate its impact on public health.

Keywords:
STI
COVID-19
Spain
Neisseria gonorrhoeae
Trends
Sexually transmitted infections
Resumen
Introducción

Las infecciones de transmisión sexual (ITS) han mostrado un incremento sostenido los últimos años. Los cambios en los patrones epidemiológicos subrayan la necesidad de adaptar estrategias de salud pública para su prevención y control. El objetivo de este estudio es describir la tendencia de los casos notificados de gonococia en Cataluña (España) durante el período 2017–2023 y comparar el patrón epidemiológico de los casos notificados antes, durante y después de la pandemia e COVID-19.

Métodos

Análisis descriptivo de los casos de gonococia notificados en Cataluña en ≥ 14 años entre 2017–2023. Se calcularon tasas de incidencia (TI) globales, por sexo, edad y origen. Se realizó un análisis descriptivo comparando los casos notificados según el periodo prepandémico (2017−2019), pandémico (2020) y pospandémico (2021−2023).

Resultados

La TI de gonococia mostró un incremento promedio del 32,9% entre 2017−2019 y del 37,9% entre 2021−2023, alcanzando 164,0 casos por 100.000 habitantes en 2023. Durante la pandemia se observaron aumentos en la proporción de casos en GBHSH (13,3%), consumo de alcohol (40,0%), ≥6 parejas sexuales (30,5%) y nueva pareja sexual (74,3%). Postpandemia, el incremento porcentual fue mayor en mujeres (115,7%), españoles (124,9%), los casos notificados en unidades de salud sexual-reproductiva (30,9%), casos sintomáticos (58,0%) y reinfecciones (33,0%). Además, disminuyó la media de edad sobre todo en mujeres, los estudios de contactos (13,1%) y la resistencia antibiótica.

Conclusiones

La gonococia continúa en aumento, especialmente entre jóvenes y mujeres. Es crucial fortalecer su visibilidad y priorizarla en los programas de prevención y control de ITS para mitigar su impacto en la salud pública.

Palabras clave:
ITS
COVID-19
España
Neisseria gonorrhoeae
Tendencias
Infecciones de transmisión sexual
Full Text
Introduction

Sexually transmitted infections (STI) are an increasingly important public health problem, both due to their high incidence and the consequences for sexual and reproductive health.1 Over the last ten years resistance rates in Europe of Neisseria gonorrhoeae to macrolides, tetracyclines and quinolones have increased, but not to ceftriaxone, which remains below 0.1%−0.2%.2

According to data from Spain's Centro Nacional de Epidemiología [National Epidemiology Centre], in recent years Catalonia has become the autonomous region with the highest incidence rates (IR) of chlamydia and gonorrhoea, with IR double the national average; 2023 figures show 78.9 cases and 71.5 cases/100,000 population respectively, mainly affecting gay males, bisexual males and other males who have sex with males (GBMSM) as well as young adults.3,4 In 2020, coinciding with the COVID-19 pandemic, gonorrhoea and particularly chlamydia infections in Catalonia and Spain decreased by 22.0% and 19.7% and by 28.2% and 21.0% respectively.3,4

The implementation of preventive measures and the adaptation of health services to the health crisis reduced the number of diagnostic tests, they significantly altered social and sexual interactions and this led to a lower reported incidence.5–7 Previous studies found that women or people living in disadvantaged areas were more affected.8

After chlamydia, gonorrhoea is therefore the curable STI with the highest reported incidence.3,4 Also in Europe, the latest report from the European Centre for Disease Prevention and Control (ECDC) highlights that, in 2022, the notification rate of gonorrhoea in the European Union/European Economic Area (EU/EEA) was the highest since 2009, with an increase of 42% compared to 2021.9 In addition, an increase was found in cases among heterosexuals and among those aged ≥ 25, especially females. Spain was fourth on the list of EU/EEA countries with the most notifications reported in 2022,9 with an annual change in IR of 18.5% from 2009 to 2020, and 30.4% from 2020 to 2022.3 As in other countries, this trend has been observed in previous years and is concentrated in the groups that accumulate more cases, such as young adults aged 25–34 and GBMSM.3,9,10

Given the growth in the number of reported cases, exceeding pre-pandemic levels, the aims of this study were: 1) to describe the trend of reported cases of gonorrhoea in Catalonia during the period 2017–2023; and 2) to compare the epidemiological pattern of the gonorrhoea epidemic before, during and after the COVID-19 pandemic.

Material and methods

The surveilance and control of STIs in Catalonia is regulated within the framework of European and national monitoring. There are two information systems for surveillance: the registry of notifiable diseases and the microbiological notification system, which make up the Catalonia STI registry, which is part of the Sistema Integrado de Vigilancia Epidemiológica de la Sida/VIH/ITS/HV (SIVES) [Integrated Epidemiological Surveillance System for AIDS/HIV/STI/HV].11 The data from these systems are integrated into the Repositori Epidemiològic de Catalunya [Catalonia Epidemiological Repository], which facilitates the complementarity of variables and the identification of cases. The declaration of gonorrhoea includes an epidemiological survey with clinical-behavioural information which accompanies the case notification.12

We carried out a descriptive analysis of reported cases of gonorrhoea during the period 2017–2023 in people aged ≥ 14. We estimated the incidence and compared the clinical-behavioural characteristics of the notifications in the period before, during, and after the pandemic, defined according to: 1) pre-pandemic, including cases from 2017 to 2019; 2) pandemic, with cases from 2020; and 3) post-pandemic, the cases reported from 2021 to 2023.

Study variables

Demographic variables included gender, age and origin, grouped according to whether the individual was born in Spain or another country. The clinical variables included were HIV co-infection, diagnosis of STI other than gonococcal disease in the 12 months prior to the reported diagnosis, symptoms, and re-infection, defined as a new gonococcal infection in a period ≥ 3 months since the previous diagnosis. The reporting department was included and classified according to whether it was a sexual-reproductive health care department (SRHCU), primary care (PC) department, STI department (STIU) or other departments (including urology, dermatology) and the beginning of the study of contacts. The microbiological variables of diagnostic technique, biological sample and antibiotic susceptibility were also incorporated.

Behavioural information on sexual orientation was included, categorised as: GBMSM, males who have sex with females (male-heterosexual) and females who have sex with males (female-heterosexual). Having a new sexual partner in ≤3 months prior to the reported episode, the number of sexual partners (0–2, 3−5, 6−10 and more than 10 partners), consumption of alcohol or other drugs, and the practice of engaging in prostitution.

Statistical analysis

The trend of reported cases during the period 2017–2023 was described through a trend analysis, applying the segmented regression model to detect change points in the number of cases per year. Annual IR per 100,000 population were calculated overall and according to gender, age group and origin. The population denominators used to calculate the rates were obtained from the Instituto de Estadística de Cataluña [Statistical Institute of Catalonia], according to the population as of 1 June of each year studied.

A descriptive analysis was performed comparing the variables of the cases reported in the three study periods. Frequencies and proportions were calculated for categorical variables and the mean and standard deviation for continuous variables. Proportions were compared using the Pearson chi-square statistical test. Differences in continuous data were assessed using ANOVA and Tukey test. All data were analysed using R software.

Ethical considerations

We used data from the EDO system, governed by the Spanish Organic Law 3/2018, of 5 December, on the Protection of Personal Data and the Guarantee of Digital Rights, and General Public Health Law 33/2011, of 4 October. Personal data were anonymised after analysis.

Results

During the period 2017–2023, 140,598 STI were notified in Catalonia. Gonorrhoea was, with 50,363 cases (35.8%), the second most notified STI after chlamydia, with 15,422 cases and representing 48.7% of all notified STI. The gonorrhoea IR showed an average annual increase of 26.9%, going from 3576 notifications and an IR of 47.7 cases/100,000 population in 2017, to 13,066 notifications and an IR of 164.0 cases/100,000 population in 2023, except for the year 2020, where IR was reduced by 22.1%, with 5010 notifications and an IR of 64.9 cases/100,000 population (Table 1). The largest annual change in IR was seen in the period 2021–2022, with an increase of 54.1%. In addition, gonorrhoea was the STI with the highest percentage increase post-pandemic (37.1%), followed by lymphogranuloma venereum (27.6%), chlamydia (22.9%) and syphilis (7.5%) (Fig. 1 and Table 1). The trend analysis identified a significant change (P = .04) in 2020. Before 2020, there was a moderate average rate increase in the number of cases of 744.5 cases/year and after 2020 a mean of 3,013.5 cases/year.

Table 1.

Changes in the incidence rate per 100,000 population of gonorrhoea by gender and origin, Catalonia 2017–2023.

Year  Total  GenderOrigin
    Male  Female  Spanish  Foreign 
Pre-pandemic
2017  47.7  80.2  16.5  27.3  101.7 
2018  56.5  93.2  21.3  37.6  135.8 
2019  83.2  135.6  32.9  54.7  198.2 
Average annual increase  32.9%  30.9%  41.8%  41.6%  39.7% 
Pandemic
2020  64.9  107.9  23.5  42.6  148.6 
Post-pandemic
2021  90.8  153.4  30.1  61.2  200 
2022  140.0  227.3  55.5  96  295.4 
2023  163.9  263.9  67  111.7  346.1 
Average annual increase  35.6%  32.1%  52.6%  36.6%  32.4% 
Fig. 1.

Changes in the number of STI cases reported in Catalonia during the period 2017–2023.

Among the total cases of gonorrhoea, 40,596 (80.6%) corresponded to men and 9767 (19.4%) to women IR increased in both men and women, although the largest increase occurred in women, with an average annual increase of 33.9%, compared to 25.4% in men, and especially in the post-pandemic period compared to the pre-pandemic period: 115.7% and 108.6% respectively. In 2017, the IR in men was 80.2 cases, increasing to 263.3 cases in 2023. In women, the IR were 16.5 and 67.0 cases respectively (Table 1). By age group, the IR was higher for women, especially among those aged 19−29, with an IR that increased from 80.7 cases in 2017 to 319.7 in 2023. In men, the IR increased, especially among those aged 29−39, from 267.0 cases in 2017 to 850.0 in 2023 (Fig. 2).

Fig. 2.

Changes in the number of cases of gonorrhoea reported in Catalonia during the period 2017–2023 by gender and age group.

The IR in foreigners was three times higher than that among Spaniards for the entire period. In foreigners, IR increased from 101.7 cases in 2017 to 346.1 in 2023, with an average annual increase of 28.7%. In Spanish nationals it went from 27.3 to 111.7 cases, with an average annual increase of 31.0%. The largest post-pandemic increase occurred in Spaniards, at 124.9%, compared to 93.2% among foreigners (Table 1).

Comparing the clinical-epidemiological characteristics of the cases reported before, during and after the pandemic (Table 2), a 30.9% increase in cases was found in SRHCU post-pandemic, decreasing by 11.2% and 10.5% in PC and STIU respectively. During the pandemic, SRHCU represented 40.4% of reported cases.

Table 2.

Clinical-epidemiological characteristics of notified cases of gonorrhoea in Catalonia according to the study period, 2017-2023.

Variables  TotalPre-COVID-19 (2017−2019)COVID-19 (2020)Post-COVID-19 (2021−2023)P 
   
Total reported cases  50,363    14,187  28.2  5015  10.0%  31,161  61.9%   
Reporting department                  <.001 
Other  2302  21.3%  717  22.5%  85  13.0%  1500  21.6%   
SRHCU  3011  27.9%  713  22.4%  265  40.4%  2033  29.3%   
PC  3625  33,6  1160  36.4%  221  33.7%  2244  32.3%   
STIU  1852  17.2%  599  18.8%  85  13.0%  1168  16.8%   
Mean age (SD)                   
Overall  31.2  10.3  31.5  10.6  31.2  10.2  31.2  10.2  <.001 
Male  33.7  9.9  32.8  9.8  33.7  9.7  33.9  9.9   
Female  28.7  10.8  30.2  11.4  28.6  10.8  28.4  10.6   
Symptoms                  .023 
Yes  16,875  57.4%  5890  56.4%  1725  57.9%  9260  58.0%   
No  12,515  42.6%  4562  43.6%  1255  42.1%  6698  42.0%   
HIV coinfection                  <.001 
Yes  4081  30.3%  1531  32.0%  456  32.4%  2094  28.7%   
No  9402  69.7%  3255  68.0%  952  67.6%  5195  71.3%   
Reinfection                  <.001 
Yes  14,255  28.3%  2633  18.6%  1338  26.7%  10,284  33.0%   
No  36,108  71.7%  11,554  81.4%  3677  73.3%  20,877  67.0%   
Previous STI                  <.001 
Yes  3158  26.5%  326  74.2%  329  25.5%  1889  29.5%   
No  8743  73.5%  940  25,8%  962  74.5%  4519  70.5%   
Study of contacts                  <.001 
Yes  8762  17.4%  3568  25.1%  1126  22.5%  4068  13.1%   
No  41,601  82.6%  10,619  74.9%  3889  77.5%  27,093  86.9%   
Sexual orientation                  <.001 
Heterosexual female  9767  27.8%  2730  26.0%  924  25.4%  6113  29.1%   
Heterosexual male  3960  11.3%  1711  16.3%  337  9.3%  1912  9.1%   
GBMSM  21,411  60.9%  6045  57.6%  2374  65.3%  12,992  61.8%   
No. partners                  <.001 
≤2  6872  60.2%  1117  34.4%  242  23.2%  1847  41.2%   
3−5  1698    528  16.3%  130  12.5%  1041  23.2%   
6−10  1488  16.9%  584  18.0%  240  23.0%  663  14.8%   
>10  1356  27.2%  1016  31.3%  431  41.3%  936  20.9%   
New partner ≥ 3 months                  <.001 
Yes  6530  68.1%  2660  71.1%  864  74.3%  3006  64.2%   
No  3056  31.9%  1079  28.9%  299  25.7%  1678  35.8%   
Drug and/or alcohol use                  .057 
Yes  3060  38.1%  1059  36.4%  274  40.0%  1727  38.9%   
No  4979  61.9%  1852  63.6%  411  60.0%  2716  61.1%   
Sex work                  <.001 
Yes  355  4.5%  142  4.9%  47  6.9%  166  3.8%   
No  7587  95.5%  2735  95.1%  639  93.1%  4213  96.2%   
Biological sample                  <.001 
Urethral  12,671  32.3%  4469  48.0%  1152  33.0%  7050  26.4%   
Vaginal  3033  7.7%  615  6.6%  251  7.2%  2167  8.1%   
Urine  3505  8.9%  632  6.8%  396  11.3%  2477  9.3%   
Pharyngeal  10,425  26.6%  1231  13.2%  885  25.3%  8309  31.2%   
Anal  6284  16.0%  1161  12.5%  525  15.0%  4598  17.2%   
Endocervical  2796  7.1%  922  9.9%  276  7.9%  1598  6.0%   
Other samples  523  1.3%  248  2.7%  0.3%  266  1.0%   
Diagnostic technique                  <.001 
Culture  38,646  76.7%  9164  64.6%  3339  66.6%  26,117  83.8%   
PCR without culture  11,717  23.3%  5023  35.4%  1676  33.4%  5044  16.2%   
Antibiotic resistance                   
Ceftriaxone  0.0%  0.0%  0.0%  0.0%  <.001 
Spectinomycin  23  0.1%  0.1%  0.0%  16  0.1%   
Ciprofloxacin  6035  15.6%  2046  22.3%  416  12.5%  3573  13.7%   
Penicillin  1663  4.3%  719  7.8%  202  6.1%  742  2.8%   
Tetracycline  1844  4.8%  478  5.2%  97  2.9%  1269  4.9%   
Cefoxitin  15  0.0%  14  0.2%  0.0%  0.0%   
Azithromycin  1235  3.2%  327  3.6%  58  1.7%  850  3.3%   
Cefixime  76  0.2%  46  0.5%  0.0%  30  0.1%   

Women had a lower mean age at diagnosis than men, 28.7 (SD: 10.8) versus 33.7 (SD: 9.9), with a downward trend, going from 30.2 to 28.4 between the pre- and post-pandemic period, while men went from an average age of 32.8 pre-pandemic to 33.9 post-pandemic (P < .001).

The proportion of symptomatic cases was significantly higher in the post-pandemic period (58.0%) compared to the pre-pandemic period (56.4%) and the pandemic period (57.9%). Similarly, the proportion of re-infections increased significantly during and after the pandemic: 26.7% and 33.0% respectively. In contrast, HIV co-infection decreased by 10.2% post-pandemic compared to the pre-pandemic period, and having a previous STI decreased during and after the pandemic by 65.7% and 60.3% respectively.

Among the behavioural characteristics, although GBMSM were the majority group in all periods (60.9%) and the group in which the greatest increase was seen during the pandemic (13.3%), cases among heterosexual women also increased by 14.4% from the pandemic period to the post-pandemic period. The proportion of cases with a new sexual partner increased to 74.3% during the pandemic period, decreasing by 13.6% post-pandemic. The same pattern was seen with alcohol consumption, being as high as 40.0% consumption during the pandemic, and having ≥ 6 sexual partners, which increased by 30.5%. The contact tracing showed a significant downward trend, from 25.1% pre-pandemic to 13.1% post-pandemic.

Among the microbiological characteristics, culture increased by 22.9% between the pre- and post-pandemic period. As regards the type of sample, a significant change was found between periods; the urethral sample was predominant before (49.5%) and during the pandemic (33.0%), while post-pandemic, pharyngeal sampling increased (31.6%). In terms of antibiotic susceptibility testing, among the cases with culture performed, 15.6% were resistant to ciprofloxacin and 4.8% and 4.3% were resistant to tetracyclines and penicillin respectively. Resistance to third-generation cephalosporins was ≤0.5%. Antibiotic resistance decreased or remained stable between the pre- and post-pandemic periods (Table 2).

Discussion

In Catalonia, there was an increase in reported cases of STI in surveillance systems,4 as was found at both national3 and European9 levels. Although chlamydia is still the STI with the highest incidence, a notable increase in reported cases of gonorrhoea was found, especially during the period 2021−2023, representing the STI with the highest percentage increase after the COVID-19 pandemic. This increase, which mainly affected women aged 19−29, was also found in Spain and in the EU/EEA.3,9 The ECDC reported an increase in cases in women aged ≤ 25 and ≤30 of more than 70% and 25% of expected cases in the second half of 2022, and 88% and 30% in the first half of 2023.9,13 This increase is believed to be indicative of behavioural changes following the relaxation of measures taken to curb the spread of COVID-19. Although social distancing and healthcare reorganisation led to a temporary decrease in reported IR,14–16 our data show that infections in GBMSM and some risky sexual behaviours, such as alcohol consumption or number of sexual partners, remained steady during the pandemic, suggesting a persistent transmission pattern despite the imposed control measures. Similarly, the increase in the proportion of symptomatic cases and re-infections and a decrease in contact tracing would point to a prioritisation of cases treated and less access during the health crisis. In the United States, where they compared cases from 2018 to 2019 to 2020–2021, they concluded that more cases with re-infections were notified during the second period.17 Among the hypotheses raised, some studies suggest that the lineage of N. gonorrhoeae circulating among the heterosexual population could cause asymptomatic or mild infections and/or greater transmissibility in contrast to circulating variants, especially among GBMSM.13 A case analysis conducted in Denmark showed that strains among heterosexuals were resistant to antibiotics recommended as first-line therapy and therefore one of the possible causes of the increase in cases and re-infections in this population group.18 Although our results do not indicate any increase in antibiotic resistance, particularly to third-generation cephalosporins, the observed susceptibility patterns for antibiotics recommended as first-line therapy indicate the need for enhanced surveillance of antimicrobial resistance and monitoring of treatment outcomes, as previously emphasised by the Euro-GASP Network.19 This is essential for the timely detection of any emergence of resistant strains and the prompt adjustment of antimicrobial treatment guidelines.

With the relaxation of restrictions, the number of cases exceeded previous levels, due to probable escalation of many of the risk behaviours after the confinement.13,20–23 In our context, although GBMSM continue to be the predominant transmission group for gonorrhoea,3,4 we must not forget the role played by bridging populations, such as men who have sex with women and men, given the significant post-pandemic increase observed among women.16,18

Among the limitations to be considered in this study, we highlight the under-reporting of the epidemiological survey to the Catalonia surveillance network, meaning the behavioural variables are limited and may be underestimated. Identifying the characteristics of the affected population and the risk factors related to infection are crucial for the development of prevention policies; therefore, reinforcing compliance with the epidemiological survey by healthcare professionals is crucial. Another limitation for interpreting our results is the lack of data on the total number of annual tests performed. Although the apparent reduction in cases during the pandemic was partly due to the interruption of services, the literature supports the idea of an increase in cases not only attributable to an increase in post-pandemic tests, but, as we mentioned above, to the escalation of risk behaviours, especially in the young population. In England, there were post-pandemic increases in diagnosis in young people, which far exceeded the growth in testing rates. This suggests a genuine increase in gonorrhoea transmission within the population.16

Addressing the substantial increases in STI cases requires urgent attention. Prioritising sexual health education and risk perception, combating the stigma associated with STI and expanding and improving access to testing and treatment are essential for any long-term strategy.24,25 Many of these recommendations are already being implemented in different countries. In Ireland, a campaign targeting 17−30-year-olds stresses the importance of condoms and raises awareness about the free home-testing service.26 Education and awareness initiatives are vital to empower people to make decisions about their sexual health. Promoting the use of barrier methods and encouraging open dialogue about STI, highlighting the importance of combining different prevention approaches to reduce their spread and promoting comprehensive sexual health, can help reduce transmission rates, especially given the undervalued use of condoms. Several studies show a worrying trend towards a decrease in condom use, especially among young people and GBMSM.27 In Spain, only 58% of young people aged 18–26 used condoms regularly, down from 62% reported in 2021. Also, only 6% use condoms during oral sex.28

It is also crucial to maintain close surveillance, to better understand the factors driving this upward trend and to identify whether this is a temporary phenomenon or whether elevated levels persist, and to be able to act accordingly. The limited implementation of contact tracing, a fundamental strategy for controlling and preventing the spread of these infections, may play an important role in their growth. Effective implementation of contact tracing, which requires collaboration between patients, healthcare professionals and health authorities, is therefore still a target we need to achieve.29

In conclusion, gonococcal infection continues to be a public health problem. The COVID-19 pandemic affected the reporting dynamics and characteristics of this infection. The changes seen in diagnostic deparments, the variation in demographic characteristics and the impact on sexual behaviours and diagnostic methods suggest that STI such as gonorrhoea continued to affect the population during the pandemic, but with modified patterns. Following the pandemic, although certain population groups such as GBMSM continue to be more affected, an increase in cases has been confirmed in other population groups, such as women and young adults. Therefore, the implementation of interventions for controling STI in our setting must be adapted to the most affected populations and include awareness of the increasing risk of STI, including educational environments, the promotion of the use of barrier methods, screening and contact notification, in addition to collecting timely and quality surveillance data.

In summary, gonorrhoea is an infection that is clearly on the rise among different population groups, with individual and population repercussions, including vertical transmission and increased antibiotic resistance. It is essential to give this infection the importance it requires and, alongside syphilis, prioritise it in prevention and control programmes and interventions for STI.

Ethical considerations

Informed consent was not required.

Funding

None received.

Declaration of competing interest

The authors have no conflicts of interest to declare.

References
[1]
M. Unemo, H.S. Seifert, E.W. Hook, S. Hawkes, F. Ndowa, J.A.R. Dillon.
Gonorrhoea.
Nat Rev Dis Primers., 5 (2019), pp. 79
[2]
D. Golparian, M.J. Cole, L. Sánchez-Busó, M. Day, S. Jacobsson, T. Uthayakumaran, et al.
Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study.
Lancet Microbe., 5 (2024), pp. e478-488
[3]
Unidad de vigilancia de VIH, ITS y hepatitis B y C. Vigilancia epidemiológica de las infecciones de transmisión sexual, 2023. Centro Nacional de Epidemiología, Instituto de Salud Carlos III/División de Control de VIH, ITS, Hepatitis virales y Tuberculosis, Dirección General de Salud Pública y Equidad en Salud; 2024.
[4]
Centre d’Estudis Epidemiològics sobres les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT). Vigilància epidemiològica de les Infeccions de Transmissió Sexual (ITS) a Catalunya. Informe anual 2022. Badalona: CEEISCAT; 2023. Available from: https://salutpublica.gencat.cat/ca/ambits/vigilancia_salut_publica/vih-sida-its-hv/Monitoratge-iavaluacio/ceeiscat/Publicacions-cientifiques/Informes/.
[5]
Z. Apalla, A. Lallas, S. Mastraftsi, A. Giannoukos, D. Noukari, M. Goula, et al.
Impact of COVID-19 pandemic on STIs in Greece.
Sex Transm Infect., 98 (2022), pp. 70
[6]
G.G. Whitlock, A. McOwan, D. Nugent, Dean Street Collaborative Group.
Gonorrhoea during COVID-19 in London, UK.
Sex Transm Infect., 97 (2021), pp. 622-623
[7]
K. Lőrincz, F.A. Meznerics, A. Jobbágy, N. Kiss, M. Madarász, L. Belvon, et al.
STIs during the COVID-19 pandemic in Hungary: gonorrhea as a potential indicator of sexual behavior.
Int J Environ Res Public Health., 19 (2022), pp. 9627
[8]
A. Sentís, A. Prats-Uribe, E. López-Corbeto, M. Montoro-Fernandez, D.K. Nomah, P.G. de Olalla, et al.
The impact of the COVID-19 pandemic on sexually transmitted infections surveillance data: incidence drop or artefact?.
BMC Public Health., 21 (2021), pp. 1637
[9]
European Centre for Disease Prevention and Control.
Gonorrhoea.
ECDC. Annual epidemiological report for 2022, ECDC, (2024),
[10]
N. Vives, R. Lugo, E. López, P. Garcia de Olalla, S. Minguell, I. Barrabeig, et al.
Increase in gonorrhoea among very young adolescents, Catalonia, Spain, January 2012 to June 2013.
[11]
Centre d’Estudis Epidemiològics sobre les ITS i Sida de Catalunya - CEEISCAT. Sistema Integrat de Vigilància Epidemiològica de la SIDA/VIH/ITS/VHC a Catalunya (SIVES 2020). 2021. Available from: http://identitatcorporativa.gencat.cat/ca/aplicacions/papereria.
[12]
Gencat. DECRET 203/2015, de 15 de setembre, pel qual es crea la Xarxa de Vigilància Epidemiològica i es regulen els sistemes de notificació de malalties de declaració obligatòria i brots epidèmics. 6958 Sep 17, 2015.
[13]
L. Nerlander, L. Champezou, J.G. Dias, G. Aspelund, L. Berlot, E. Constantinou, et al.
Sharp increase in gonorrhoea notifications among young people, EU/EEA, July 2022 to June 2023.
[14]
S.M. Jenness, A. le Guillou, C. Chandra, L.M. Mann, T. Sanchez, D. Westreich, et al.
Projected HIV and bacterial STI incidence following COVID-related sexual distancing and clinical service interruption.
J Infect Dis., 223 (2021), pp. 1019-1028
[15]
V. Soriano, H. Blasco-Fontecilla, L. Gallego, J.V. Fernández-Montero, C. de Mendoza, P. Barreiro.
Rebound in sexually transmitted infections after the COVID-19 pandemic.
AIDS Rev., 25 (2023), pp. 127-135
[16]
H. Fountain, S.J. Migchelsen, H. Charles, T. Ram, H. Fifer, H. Mohammed, et al.
Rebound of gonorrhea after lifting of COVID-19 preventive measures, England.
Emerg Infect Dis., 30 (2024), pp. 329-332
[17]
M.E. Coen, S.L. Williford, R. Muvva, B. Genberg, A. Greenbaum, C.M. Schumacher.
Characteristics of reported gonorrhea diagnoses during the COVID-19 pandemic compared with pre-COVID-19 pandemic, Baltimore City, Maryland.
Sex Transm Dis., 50 (2023), pp. 215-223
[18]
T.R. Pedersen, M. Wessman, M. Lindegaard, S. Hallstrøm, C. Westergaard, I. Brock, et al.
Gonorrhoea on the rise in Denmark since 2022: distinct clones drive increase in heterosexual individuals.
[19]
M.J. Cole, C. Quinten, S. Jacobsson, M. Day, A.J. Amato-Gauci, N. Woodford, et al.
The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area.
BMC Infect Dis., 19 (2019), pp. 1040
[20]
Z. Apalla, A. Lallas, S. Mastraftsi, A. Giannoukos, D. Noukari, M. Goula, et al.
Impact of COVID-19 pandemic on STIs in Greece.
Sex Transm Infect., 98 (2022), pp. 70
[21]
S.M. Jenness, A. le Guillou, C. Chandra, L.M. Mann, T. Sanchez, D. Westreich, et al.
Projected HIV and bacterial STI incidence following COVID-related sexual distancing and clinical service interruption.
J Infect Dis., 223 (2021), pp. 1019-1028
[22]
C.N. Pinto, J.K. Niles, H.W. Kaufman, E.M. Marlowe, D.P. Alagia, G. Chi, et al.
Impact of the COVID-19 pandemic on Chlamydia and gonorrhea screening in the U.S.
Am J Prev Med., 61 (2021), pp. 386-393
[23]
K.A. Stanford, J.A. Mason, E.E. Friedman.
Trends in STI testing and diagnosis rates during the COVID-19 pandemic at a large urban tertiary care center, and the role of the emergency department in STI care.
Front Reprod Health., 5 (2023),
[24]
Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations, World Health Organization, (2022),
[25]
A. Van Ahee, K. Combs, V. Delpech, S. Desai, J.S. Finne, M. Hoekstra, et al.
Public health guidance on HIV, hepatitis B and C testing in the EU/EEA: an integrated approach.
ECDC, (2018),
[26]
S.L. Shih, A.S. Graseck, G.M. Secura, J.F. Peipert.
Screening for sexually transmitted infections at home or in the clinic?.
Curr Opin Infect Dis., 24 (2011), pp. 78-84
[27]
L.E. Szucs, R. Lowry, A.M. Fasula, S. Pampati, C.E. Copen, K.S. Hussaini, et al.
Condom and contraceptive use among sexually active high school students - youth risk behavior survey, United States, 2019.
MMWR Suppl., 69 (2020), pp. 11-18
[28]
Sociedad Española de Contracepción (SEC).
Encuesta de Anticoncepción en España, (2022),
[29]
T. Folke, A.S. Menon-Johansson.
An evaluation of digital partner notification tool engagement and impact for patients diagnosed with gonorrhea and syphilis.
Sex Transm Dis., 49 (2022), pp. 815-821
Copyright © 2024. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Download PDF
Article options
Tools